SI2723363T1 - Kombinacijska terapija za ishemijo - Google Patents

Kombinacijska terapija za ishemijo

Info

Publication number
SI2723363T1
SI2723363T1 SI201231412T SI201231412T SI2723363T1 SI 2723363 T1 SI2723363 T1 SI 2723363T1 SI 201231412 T SI201231412 T SI 201231412T SI 201231412 T SI201231412 T SI 201231412T SI 2723363 T1 SI2723363 T1 SI 2723363T1
Authority
SI
Slovenia
Prior art keywords
ischemia
combination therapy
therapy
combination
Prior art date
Application number
SI201231412T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael Tymianski
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of SI2723363T1 publication Critical patent/SI2723363T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Dermatology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Nuclear Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201231412T 2011-06-24 2012-06-23 Kombinacijska terapija za ishemijo SI2723363T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161501117P 2011-06-24 2011-06-24
US201261617001P 2012-03-28 2012-03-28
EP12802409.8A EP2723363B1 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia
PCT/IB2012/053178 WO2012176172A2 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia

Publications (1)

Publication Number Publication Date
SI2723363T1 true SI2723363T1 (sl) 2018-12-31

Family

ID=47423033

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231412T SI2723363T1 (sl) 2011-06-24 2012-06-23 Kombinacijska terapija za ishemijo

Country Status (19)

Country Link
US (3) US10064910B2 (enExample)
EP (3) EP4052721A1 (enExample)
JP (5) JP6401057B2 (enExample)
KR (5) KR102425466B1 (enExample)
CN (1) CN103648518B (enExample)
AU (1) AU2012274910B2 (enExample)
CA (1) CA2839630A1 (enExample)
CY (1) CY1121379T1 (enExample)
DK (2) DK3427748T3 (enExample)
ES (2) ES2912042T3 (enExample)
HR (2) HRP20220519T1 (enExample)
HU (2) HUE040564T2 (enExample)
LT (1) LT2723363T (enExample)
PL (2) PL3427748T3 (enExample)
PT (2) PT3427748T (enExample)
RS (1) RS57798B1 (enExample)
SI (1) SI2723363T1 (enExample)
SM (1) SMT201800592T1 (enExample)
WO (1) WO2012176172A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
EP3074030A4 (en) * 2013-11-26 2017-08-16 Trustees of Dartmouth College Method for mitigating or alleviating synaptic and cognitive deficits
FR3021319B1 (fr) * 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
CZ309217B6 (cs) * 2014-05-27 2022-06-01 Ústav Organické Chemie A Biochemie Av Čr, V.V.I. Lipidované peptidy jako neuroprotektiva
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN104497106B (zh) * 2014-12-05 2017-05-10 华中科技大学 一种小分子多肽、其应用及产品
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
US11229675B2 (en) 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯(北京)生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
CN106265594B (zh) * 2016-09-21 2019-07-26 南京医科大学 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法
CN106749559B (zh) * 2016-11-23 2020-09-04 郑州大学 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法
JP7109958B2 (ja) * 2017-04-04 2022-08-01 キヤノンメディカルシステムズ株式会社 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN110799522B (zh) * 2017-07-05 2023-08-29 拜西欧斯(北京)生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
EP3693001A4 (en) * 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
US12122811B2 (en) 2018-04-06 2024-10-22 Northwestern University BDNF mimetic peptide amphiphiles
JP7158904B2 (ja) * 2018-06-14 2022-10-24 社会福祉法人 恩賜財団済生会熊本病院 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
EP4106818A4 (en) * 2020-02-19 2024-03-20 NoNO Inc. Inhibition of reperfusion injury with a psd-95 inhibitor
CA3171307A1 (en) * 2020-02-19 2021-08-26 Nono Inc. Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
GB2617371A (en) * 2022-04-06 2023-10-11 Perspectum Ltd Method and apparatus for characterization of breast tissue using multiparametric MRI
WO2024149230A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 一种神经保护性psd-95多肽抑制剂及其应用
CN117422722B (zh) * 2023-12-19 2024-03-29 北京智源人工智能研究院 基于adc图像的肿瘤预后特征评估的方法和装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742152B1 (fr) 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
AU2004233862A1 (en) 2003-04-25 2004-11-11 Mitos Pharmaceuticals, Inc. Prophylactic pretreatment with antioxidants
BRPI0409865A (pt) 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
JP2007505159A (ja) * 2003-05-19 2007-03-08 ザ ケネス エス.ウォーレン インスティテュート,インコーポレーテッド 延長された治療ウインドウを有する、応答性細胞、組織および器官の保護、回復および増強のための組織保護サイトカイン
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
CA2657665C (en) * 2006-07-11 2015-06-02 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
GB0707348D0 (en) 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
PL2205623T3 (pl) 2007-10-29 2016-09-30 Ochronne tetrapeptydy do pielęgnacji skóry
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101720760B1 (ko) 2008-01-25 2017-03-28 오르후스 우니베르시테트 Igfbp-4에 대한 papp-a 활성의 선택적 엑소사이트 억제
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CA2665302A1 (en) 2009-05-01 2010-11-01 Universite De Montreal Cd36 modulation and uses thereof
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
PT2440231T (pt) 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
US20110144029A1 (en) 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2012354072B2 (en) 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
JP2014520142A (ja) 2014-08-21
WO2012176172A2 (en) 2012-12-27
PT3427748T (pt) 2022-05-03
JP2017193535A (ja) 2017-10-26
AU2012274910A1 (en) 2014-01-16
KR102140169B1 (ko) 2020-07-31
SMT201800592T1 (it) 2019-01-11
CY1121379T1 (el) 2020-05-29
PL3427748T3 (pl) 2022-05-30
EP2723363A4 (en) 2014-12-10
RS57798B1 (sr) 2018-12-31
KR20220106862A (ko) 2022-07-29
JP7085457B2 (ja) 2022-06-16
DK2723363T3 (en) 2018-10-15
HRP20181526T1 (hr) 2018-12-14
JP2020189859A (ja) 2020-11-26
CA2839630A1 (en) 2012-12-27
US20190091283A1 (en) 2019-03-28
KR20210109661A (ko) 2021-09-06
KR102296106B1 (ko) 2021-08-30
KR102425466B1 (ko) 2022-07-25
EP2723363A2 (en) 2014-04-30
LT2723363T (lt) 2018-10-25
EP4052721A1 (en) 2022-09-07
US10967041B2 (en) 2021-04-06
US11878044B2 (en) 2024-01-23
DK3427748T3 (da) 2022-04-19
HUE040564T2 (hu) 2019-03-28
KR20190107195A (ko) 2019-09-18
PL2723363T3 (pl) 2018-12-31
US10064910B2 (en) 2018-09-04
ES2690994T3 (es) 2018-11-23
EP3427748B1 (en) 2022-03-02
KR20200092437A (ko) 2020-08-03
HRP20220519T1 (hr) 2022-05-27
HUE058238T2 (hu) 2022-07-28
JP2022188068A (ja) 2022-12-20
JP7143374B2 (ja) 2022-09-28
JP6401057B2 (ja) 2018-10-03
KR102022116B1 (ko) 2019-09-18
PT2723363T (pt) 2018-11-08
WO2012176172A3 (en) 2013-03-28
CN103648518A (zh) 2014-03-19
KR20140053971A (ko) 2014-05-08
EP2723363B1 (en) 2018-08-29
US20210308209A1 (en) 2021-10-07
CN103648518B (zh) 2016-11-16
EP3427748A1 (en) 2019-01-16
JP2019038831A (ja) 2019-03-14
US20140248257A1 (en) 2014-09-04
ES2912042T3 (es) 2022-05-24
AU2012274910B2 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
SMT201800592T1 (it) Terapia di combinazione per ischemia
ZA201305897B (en) Combination therapy
TWI560388B (en) Dampferzeugerheizrohrreparaturmittel und reparaturverfahren
IL233154A0 (en) compounds
GB201106395D0 (en) Compounds
GB201109763D0 (en) Compounds
ZA201306857B (en) Mesogen-containing compounds
ZA201400120B (en) Combination therapy
GB201107197D0 (en) Compounds
GB201122139D0 (en) Compounds
EP2691581A4 (en) joint assembly
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
EP2701744A4 (en) COMBINATION THERAPY
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201118613D0 (en) Compounds
GB201114226D0 (en) Combination therapy
GB201106339D0 (en) Combination
GB201116007D0 (en) Combination
GB201117693D0 (en) Combination
GB201121105D0 (en) Combination
GB201116059D0 (en) Project P
GB201110793D0 (en) Easy carry
GB201114533D0 (en) Concept 36A